Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) EBT (2021 - 2025)

Aligos Therapeutics' EBT history spans 5 years, with the latest figure at -$19.9 million for Q4 2025.

  • For Q4 2025, EBT rose 75.83% year-over-year to -$19.9 million; the TTM value through Dec 2025 reached -$23.9 million, up 81.76%, while the annual FY2025 figure was -$23.9 million, 81.76% up from the prior year.
  • EBT reached -$19.9 million in Q4 2025 per ALGS's latest filing, up from -$31.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $43.1 million in Q1 2025 to a low of -$82.1 million in Q4 2024.
  • Average EBT over 5 years is -$23.3 million, with a median of -$22.4 million recorded in 2022.
  • The largest YoY upside for EBT was 223.8% in 2025 against a maximum downside of 398.63% in 2025.
  • A 5-year view of EBT shows it stood at -$37.8 million in 2021, then skyrocketed by 42.19% to -$21.8 million in 2022, then dropped by 27.87% to -$27.9 million in 2023, then tumbled by 194.12% to -$82.1 million in 2024, then surged by 75.83% to -$19.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's EBT are -$19.9 million (Q4 2025), -$31.5 million (Q3 2025), and -$15.7 million (Q2 2025).